ctDNA sensitivity in early-stage disease

Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, discusses remaining challenges in implementing circulating tumor DNA (ctDNA)-based approaches in clinical practice, highlighting difficulties in detecting early-stage disease which may result in false negatives. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Be the first to comment